Stock A204840 GL PHARM TECH CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials GL Pharm Tech Corp.

Equities

A204840

KR7204840003

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
1,226 KRW -0.16% Intraday chart for GL Pharm Tech Corp. -5.40% +7.92%
05-03 An undisclosed buyer acquired 3.23% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund for KRW 3.97 billion. CI
03-06 W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. from Ideal Private Equity Fund CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 129,718 39,363 68,455 76,699 46,578 70,834
Enterprise Value (EV) 1 142,044 54,399 71,982 78,389 55,848 84,484
P/E ratio -22.4 x -7.14 x -19.3 x -16.9 x -57.7 x -18.9 x
Yield - - - - - -
Capitalization / Revenue 16.2 x 3.71 x 5.71 x 6.17 x 2.78 x 2.72 x
EV / Revenue 17.8 x 5.13 x 6 x 6.31 x 3.34 x 3.25 x
EV / EBITDA -41.4 x -42.6 x -103 x -118 x -50.3 x -77.5 x
EV / FCF -17.3 x 117 x -26.7 x -27.2 x -8.02 x -31.6 x
FCF Yield -5.77% 0.85% -3.75% -3.68% -12.5% -3.16%
Price to Book 16.6 x 16.7 x 4.96 x 4.55 x 2.89 x 5.77 x
Nbr of stocks (in thousands) 35,784 35,784 47,210 61,854 62,104 62,354
Reference price 2 3,625 1,100 1,450 1,240 750.0 1,136
Announcement Date 19-03-13 20-03-29 21-03-19 22-03-17 23-03-17 24-03-18
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7,998 10,608 11,988 12,426 16,729 26,033
EBITDA 1 -3,434 -1,278 -696.4 -666.9 -1,110 -1,090
EBIT 1 -4,579 -3,127 -2,645 -2,707 -3,255 -3,228
Operating Margin -57.25% -29.48% -22.06% -21.78% -19.46% -12.4%
Earnings before Tax (EBT) 1 -5,392 -5,558 -3,467 -3,842 -832.4 -3,944
Net income 1 -5,350 -5,515 -3,356 -3,727 -790.2 -3,749
Net margin -66.88% -51.99% -28% -30% -4.72% -14.4%
EPS 2 -161.8 -154.1 -75.00 -73.29 -13.00 -60.00
Free Cash Flow 1 -8,194 464.2 -2,698 -2,882 -6,965 -2,672
FCF margin -102.45% 4.38% -22.5% -23.19% -41.63% -10.26%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-13 20-03-29 21-03-19 22-03-17 23-03-17 24-03-18
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 12,326 15,036 3,527 1,690 9,270 13,650
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -3.59 x -11.76 x -5.065 x -2.534 x -8.351 x -12.52 x
Free Cash Flow 1 -8,194 464 -2,698 -2,882 -6,965 -2,672
ROE (net income / shareholders' equity) -77.8% -108% -40.3% -23.5% -4.71% -26.4%
ROA (Net income/ Total Assets) -12.3% -6.73% -5.38% -5.06% -5.59% -5%
Assets 1 43,540 82,001 62,424 73,631 14,129 74,991
Book Value Per Share 2 218.0 66.00 293.0 272.0 259.0 197.0
Cash Flow per Share 2 48.40 9.060 201.0 100.0 74.70 66.30
Capex 1 2,401 989 1,098 1,328 6,438 579
Capex / Sales 30.02% 9.32% 9.16% 10.69% 38.49% 2.23%
Announcement Date 19-03-13 20-03-29 21-03-19 22-03-17 23-03-17 24-03-18
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GL PHARM TECH CORP. Stock GL Pharm Tech Corp.
+7.92% 69.01M
MODERNA, INC. Stock Moderna, Inc.
+23.37% 46.71B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.94% 41.52B
CELLTRION, INC. Stock Celltrion, Inc.
-5.86% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.29% 25.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.92% 19.26B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+3.20% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.67% 12.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.23% 11.98B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A204840 Stock
  4. Financials GL Pharm Tech Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW